Search research articles

お問い合わせ

JoVEについて

概要リーダーシップブログ JoVEヘルプセンター

著者向け

出版プロセス編集委員会範囲と方針査読よくある質問投稿

図書館員向け

推薦の声購読アクセスリソース図書館諮問委員会よくある質問

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments アーカイブ

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教員リソースセンター教員サイト

プライバシーポリシー

関連する概念動画

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Chronic Inflammation: Introduction

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え

Same author

Problems of Anticoagulant Control-II, Which Test?

Bristol medico-chirurgical journal (1963)·2017

Same author

Monoclonal and/or Oligoclonal Immunoglobulins in Sera of Patients with Non-Hodgkin's Lymphomas, Determined by Iso-Electric Focusing and Immunoblotting.

Leukemia & lymphoma·2016

Same author

B Cell Malignancies Frequently Target the Autoreactive B Cell Repertoire.

Leukemia & lymphoma·2016

Same author

CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3.

Leukemia & lymphoma·2016

Same author

Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Leukemia·2014

Same author

"Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''.

Blood cancer journal·2013

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連記事をすべて見る

Search research articles

関連する実験動画

Updated: Jul 6, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

慢性リンパ球性白血病は慢性リンパ球性白血病である.

G Dighiero¹, T J Hamblin

¹Institut Pasteur de Montevideo, Montevideo, Uruguay.

Lancet (London, England)

|March 25, 2008

まとめ

この要約は機械生成です。

慢性リンパ球性白血病 (CLL) は,年配の成人における常見の血液がんであり,結果は変動します. 分子マーカーの進歩は,予後評価を改善しますが,新しい治療法にもかかわらず,CLLは依然として不治です.

さらに関連する動画

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

関連する実験動画

Last Updated: Jul 6, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

科学分野:

血液学ヘマトロジ
腫瘍学腫瘍学
分子生物学は分子生物学である.

背景:

慢性リンパ球性白血病 (CLL) は,ヨーロッパと北米で最も一般的な白血病であり,主に高齢者に影響します.
CLLは高度に変動する臨床経過を示し,患者の生存期間は数ヶ月から数十年までである.
進歩にもかかわらず,CLLは依然として不治の悪性腫瘍であり,ほとんどの患者は治療後に再発を経験しています.

研究の目的:

CLL疾患の進行を予測するための分子および細胞マーカーの特定における最近の進展をレビューする.
B細胞受容体機能,遺伝病変,アポトーシスのより深い理解が,予後と管理にどのように影響するかについて議論します.
新しい治療薬がCLLの合理的かつ効果的な管理に与える影響を調査する.

主な方法:

CLLにおける分子および細胞遺伝的マーカーに関する現在の文献のレビュー.
CLLの病原性におけるB細胞受容体シグナル伝達,遺伝子変異,アポトーシスの役割の分析.
CLLの管理における新しい治療薬の有効性の評価.

主要な成果:

免疫グロブリン遺伝子変異プロファイルと細胞遺伝異常は,CLLにおける主要な予後予測要因である.
B細胞受容体機能,遺伝病変,アポトーシスの理解は,疾患の進行に関する洞察を提供します.
新しい治療薬は,CLL管理の合理性と効果を向上させていますが,まだ治癒は達成されていません.

結論:

分子および細胞マーカーは,慢性リンパ球性白血病の予後評価を大幅に改善します.
治療法がより効果的になっているが,慢性リンパ球性白血病は依然として困難で治癒不可能な病気である.
CLLの病理生理学と新しい治療法に関するさらなる研究は,患者のアウトカムを改善するために不可欠です.